Enhance your data by adding SomaScan® Assay services to your mass spectrometry analysis
Analyze thousands of proteins in 55 µL of plasma, and obtain sensitive detection without complex sample preparation
Adding the SomaScan Assay to mass spectrometry allows for deeper molecular insights, rapidly and consistently
Pairing the SomaScan Assay with complementary technologies, such as mass spectrometry, can accelerate target identification and protein expression analysis, as well as help you differentiate causal links or find new uses for already approved therapeutics.
The SomaScan Assay is based on SOMAmer® (Slow Off-Rate Modified Aptamer) Reagents, which are aptamers that are custom-engineered to have enhanced shape complementarity to their targets, as well as slow off rates for longer target binding. A universal polyanionic competitor further enhances specificity to the target protein.
Our high-plex proteomics platform can measure thousands of proteins simultaneously from a small sample (~55 µL) of plasma, serum, CSF, and multiple other complex sample types (human and non-human). This platform also offers excellent reproducibility with median coefficients of variation (CVs) of ~5%.
Published findings show the benefit of using complementary technologies
- In patients with high-grade serous ovarian carcinoma, researchers used the SomaScan Assay and mass spectrometry to discover protein signatures classifying long- or short-term relapse-free survivors (PMID 31588238)
- Researchers used the SomaScan Platform and mass spectrometry to help identify the role of molecular mechanisms in different pathophysiological processes in COVID-19, a complex, heterogeneous condition. These insights may help stratify patients in clinical trials and in the clinic for targeted treatment (PMID 33724185)
- In a study combining the SomaScan Assay with mass spectrometry analysis, research identified aspirin-targeted proteins that are potentially associated with the risk of colorectal cancer (PMID 33318029)
Advantages of a complementary approach
Precision proteomics for diagnostics, drug discovery, and health management
Featuring: Nelson Trujillo, MD
Boulder Community Health
“The resulting prediction of individualized and near-term risk enabled Trujillo to advise 45% of his evaluated patients to change therapy.”
A proteomic tool to separate clinical signals from a sea of noise
Featuring: Antoine Dufour, PhD
University of Calgary
“As an initial screen, it’s a game-changer
in terms of numbers.”
Profiling technology unlocks the predictive power of proteomics
Peter Ganz, MD
University of California, San Francisco
Ali Javaheri, MD
Washington University in St. Louis
Yuichi Shimada, MD
“From a single blood sample, one can simultaneously determine the risk of many diseases.”
Benefits of the SomaScan Assay
The SomaScan Assay utilizes small sample volumes and delivers high-quality, actionable data to accelerate your research.
The SomaScan Assay can measure proteins with low limits of detection (10-log range with fM sensitivity).
(~5% median CV)
Obtain consistent and reproducible inter- and intra- assay results for data analysis and comparison.
Enable 11,000 total protein measurements per sample, and conduct high-throughput analysis of >1,000 samples per day.
The SomaScan Platform offers multiple ways to complement your mass spectrometry analysis
SomaScan Assay Services
With the ability to profile thousands of proteins simultaneously in samples such as blood, urine, and cerebrospinal fluid, the SomaScan Assay lets you measure low- and high-abundant proteins with confidence.
Choose your proteins of interest, and customize a panel. Or select from one of our carefully curated disease-specific panels, including neuroscience, cardiovascular disease, cytokines and more.
Run the SomaScan Assay in your own lab as a SomaLogic Authorized Site. Having the technology onsite enables you to accelerate your workflow, automate your process, and create revenue-generating capabilities.
Learn more with these SomaScan Assay resources
SomaScan 11K Assay v5.0
The SomaScan Platform is a powerful tool with applications in scientific research and health and wellness. This technical note provides background on the platform itself, as well as performance metrics for the SomaScan 11K Assay v5.0.
SomaScan 7K Assay v4.1
The SomaScan Platform measures native proteins in complex matrices by transforming available binding sites on individual proteins into a corresponding SOMAmer Reagent concentration, which is then quantified by hybridization to microarrays.
Controlling pre-analytical variation is important to avoid misleading analyses that can impact data and cause setbacks in research efforts – costing time, money, and loss of precious samples.
Elements of Specificity
Each SOMAmer Reagent is characterized by two elements of specificity: strong affinity for its target protein and a slow dissociation rate. These two specificity attributes derive from the unique chemical composition of each reagent.